When NBA rookies land on stacked teams, they get less playing time, less visibility, and lower long-term earnings. Early exposure matters for careers.

Impressive investigation into how drug companies have financial ties to the IRBs that oversee their clinical trials (courtesy of private equity IRBs). Spoiler alert: IRB conflicts of interest are bad news for patient safety. By Walt Bogdanich, Carson Kessler , and Jeremy Singer-Vine Gift

What Americans die from vs what the media reports on. Terrorism and homicides get more than half of the coverage though they represent a tiny fraction of deaths. Conversely, heart disease and cancer get only a few per cent of the coverage though more than half die from them.

Josh Merfeld Alp D. Yel Dina D. Pomeranz 🟣 Sort of continuous now. Feel free to submit PRs :) github.com/Davidvandijcke…

Consolidation in the EHR market -- where there are 2 dominant vendors -- is creating a big risk of a catastrophic cybersecurity event. A Jay Holmgren, Nate Apathy, and I ponder the possibility of a "single-point-of-failure" risk in the EHR market in this Health Affairs Scholar

Age of Nobel Laureates by Category (1901–2025)

Economics apparently doing MUCH better than other sciences when it comes to p-hacking:

And right on schedule... about 1/3 of FDA appointees go to industry within 2 years after their exit from the agency healthaffairs.org/doi/10.1377/hl…

My favorite dataviz expert Paul G-P has a constantly updated chart for the economics job market on his website. Link below:

BREAKING: Friday night massacre underway at CDC. Dozens of "disease detectives," high-level scientists, entire Washington staff and editors of the MMWR (Morbidity and Mortality Weekly Report) have all been RIFed and received the following notice:

New: ‘It’s a massacre’: CDC battered by government shutdown firings statnews.com/2025/10/11/cdc… via STAT

BREAKING: Some of the layoffs at CDC are being REVERSED. Here is my updated story. washingtonpost.com/health/2025/10…

🚨 2025 Nobel Prize in Economics goes to Mokyr, Aghion and Howitt 🚨 "for having explained innovation-driven economic growht" The best prize in years!

Nobel Prize time! This morning the The Nobel Prize committee made a great choice; Joel Mokyr, Philippe Aghion, and Peter Howitt! They were recognized for their groundbreaking work on innovation, creative destruction, and the drivers of long-term economic growth. While this is

Exclusive: How political pressure is shaping the work of the FDA, from searching for autism treatments to heavily focusing on Covid-19 vaccine adverse events. Read for more details on how the leucovorin decision came about, in particular: statnews.com/2025/10/14/fda…

Breaking: USC has rejected President Trump's controversial education compact. The university's interim president Beong-Soo Kim said in a statement that he had sent a letter to the U.S. Department of Education turning down the Trump offer: latimes.com/california/sto…

J-E-T-S! No, not the winless football team. I'm talking private jets owned by six of the largest drugmakers, which have descended on DC more than 120 times this year. The extensive travel comes as the industry works to withstand a number of policy fights. endpoints.news/top-drugmakers…

exclusive: Richard Pazdur, just tapped by Trump administration to be FDA's top drug regulator, has privately warned that some of the agency's new initiatives could be illegal and dangerous. w Rachel Roubein washingtonpost.com/health/2025/11…

BREAKING scoop: Top drug regulator Rick Pazdur filed papers to retire from the FDA at the end of this month, according to agency sources. He alerted leaders at the drug center this morning. He could still withdraw the papers. statnews.com/2025/12/02/ric…

From the The New York Times: The US is Funding Fewer Grants in Every Area of Science and Medicine Gift-link: nytimes.com/interactive/20…